Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356778 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL581064 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL514303 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL5651324 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL2805477 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL2305639 | 1.00 | CES1 (0.35) | CES1 | |
| SCHEMBL3857734 | 0.98 | CES1 (0.32) | CES1 | |
| SCHEMBL290664 | 0.92 | — | — | |
| SCHEMBL15792000 | 0.80 | CES1 (0.35) | CES1 | |
| SCHEMBL8000974 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319446-A1 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2011-12-29 | — | — | US | disclosed |
| US-7994211-B2 | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses | ARGENTA DISCOVERY LIMITED (GB) | 2011-08-09 | — | — | US | disclosed |
| US-20100144852-A1 | Bicyclo[2.2.1]hept-7-ylamine Derivatives and Their Uses | ARGENTA DISCOVERY LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-1924553-A1 | BICYCLO[2.2.]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008017824-A1 | BICYCLO [2. 2. 1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007017670-A1 | BICYCLO[2.2.]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144852-A1 | Bicyclo[2.2.1]hept-7-ylamine Derivatives and Their Uses | CHRM2, CHRM3, CHRM1 | CES1 1294/4885 |
| US-20110319446-A1 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | CHRM2, CHRM3, CHRM1 | CES1 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.